Medicine prices in urban Mozambique: A public health and economic study of pharmaceutical markets and price determinants in low-income settings

Health Policy and Planning

Volumn 25, Issue 1, 2010, Pages 70-84

  Russo, Giuliano ^a   McPake, Barbara ^b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b QUEEN MARGARET UNIVERSITY   (United Kingdom)

Author keywords

Health economics; Health sector reform; Pharmaceutical industry; Pharmaceutical policy; Regulation

Indexed keywords

COMMERCE; DRUG COSTS; DRUG INDUSTRY; GOVERNMENT REGULATION; HEALTH CARE REFORM; HUMANS; MOZAMBIQUE; PHARMACEUTICAL PREPARATIONS; POVERTY; PUBLIC HEALTH; URBAN POPULATION;

EID: 73849146873     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czp042     Document Type: Article

References (61)

1. Babar ZU, Ibrahim MI, Singh H, Bukahri NI, Creese A. 2007. Evaluating drug prices, availability, and price components: implications for access to drugs in Malaysia. PLOS Medicine 4: 466-475
2. Bain JS. 1956. Barriers to new competition: their character and consequences in manufacturing industries. Cambridge, MA: Harvard University Press.
3. Barker C. 1983. The Mozambique pharmaceutical policy. The Lancet 2: 780-782
4. Chao S, Kostermans K. 2002. Improving health for the poor in Mozambique: the fight continues. HNP discussion paper. Washington, DC: World Bank.
5. Chonguiça CM, Durão JR. 2004. Importação de medicamentos para o sector privado em Moçambique. Legislação e regulamentação. Documento base ''workshop'' com órgãos de comunicação social. Maputo: Pharmaceutical Department, Ministry of Health.
6. Cumbi AJ. 2002. Evaluation of service quality and rational use of drugs in Mozambique. Swiss Development Cooperation programme in Mozambique, Maputo.
7. Danzon PM, Furukawa MF. 2003. Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs 25 (Suppl web exclusives):W3-521- 536
8. DeFraja G, DelBono F. 1989. Alternative strategies of a public enterprise in oligopoly. Oxford Economic Papers 41: 302-311
9. Donsimoni M-P, Geroski P, Jacquemin A. 1984. Concentration indices and market power: two views. Journal of Industrial Economics 32: 419-434
10. Dukes G, Russo G et al. 2003. Evaluation of the pharmaceutical area in Mozambique: its current performance and prospects of its future development. Copenhagen: Euro Health Group.
11. Ensor T, Cooper T. 2004. Overcoming barriers to health service access: influencing the demand side. Health Policy and Planning 19: 69-79.
12. Ensor T, Weinzierl S. 2006. A review of regulation in the health sector in low and middle income countries. OPM Working Paper. Oxford: Oxford Policy Management.
13. Everard M. 2003. Access to medicines in low-income countries. In: Dukes GMN, De Joncheere CP, Rietveld AH, Haaijer-Ruskamp FM (eds). Drugs and money. Amsterdam: IOS Press.
14. Folkedal G, Kostermans K. 1997. Public procurement of pharmaceuticals in Mozambique: a review of practices in the 90s. Washington, DC: World Bank.
15. Gelders S, Ewen M, Noguchi N, Laing R. 2006. Price, availability and affordability. An international comparison of chronic disease medicines. Cairo: WHO Regional Office for the Eastern Mediterranean/Health Action International. WHO-EM/EDB/068/E.
16. Goodman C, Kachur SP, Abdulla S et al. 2004. Retail supply of malariarelated drugs in rural Tanzania: risks and opportunities. Tropical Medicine and International Health 9: 655-663
17. Government of Mozambique. 1990. Diploma Ministerial No. 109/90. Boletim da Republica I Serie (52).
18. Government of Mozambique. 1998. Lei do Medicamento. Boletim da República 1/2 (Lei N8 4/98).
19. Government of Mozambique. 1999. Regulamento do Sistema do Registo. Boletim da República 22 (Decreto N822/99).
20. Government of Mozambique. 2003. Regulamento do Regime de Abertura de Farmácias. Boletim da República I Série (14).
21. Government of Mozambique. 2006. Plano de Redução da Pobreza Absoluta 2006-2009 (PARPA II), Observatório da pobreza do MPD, Maputo.
22. Hanlon J. 1996. Peace without profit: How the IMF blocks rebuilding in Mozambique. Oxford: James Currey.
23. Harris RG, Wiens EG. 1980. Government enterprise: an instrument for the internal regulation of industry. Canadian Journal of Economics XIII: 125-132
24. Health Action International (HAI). (2006). 11 African countries launch medicine price information. Online at: http://www.haiafrica.org/, accessed 14 December 2006.
25. Hongoro C, Kumaranayake L. 2000. Do they work? Regulating for-profit providers in Zimbabwe. Health Policy and Planning 15: 368-377
26. Hotelling H. 1929. Stability in competition. Economic Journal 39: 41-57.
27. Huttin C. 1996. A critical review of the remuneration systems for pharmacists. Health Policy 36: 53-68.
28. INE. 2005. Resultados comparativos preliminares dos IAF 1997 e 2003. Maputo: Istituto Nacional de Estatística.
29. Jacobzone S. 2000. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Labour Market and Social Policy occasional papers. Paris: OECD.
30. Kumaranayake L, Hongoro C, Lake S, Mujinja P, Mpembeni R. 2003. Coping with private health markets - regulatory in effectiveness in sub-Sahara Africa. In: Soderlund N, Mendoza-Arana P, Goudge J (eds). The new public/private mix in health: exploring the changing landscape. Geneva: World Health Organization.
31. Lindelow M, Ward P, Zorzi N. 2004. Primary health care in Mozambique: service delivery in a complex hierarchy. Africa Region Human Development Working Paper Series. Washington, DC: World Bank.
32. McPake B, Hanson K, Mills A. 1992. Implementing the Bamako Initiative: a review and five case studies. PHP Departmental Publication, no.8. London School of Hygiene & Tropical Medicine.
33. Ministry of Health. 2003. Importação de medicamentos para o sector privado. Dados estatísticos e análise dos BIEFS. Maputo.
34. Ministry of Health, South Africa. 2005. Medicine pricing. A mandate to make quality medicine accessible and affordable. Online at http://www.doh.gov. za/docs/pr/2005/pr0124.html.
35. Ministry of Planning, & Financing, Ministry of Health.2003. A despesa pública com a Saúde em Moçambique. Maputo: Principia.
36. Mossialos E, Mrazek M, Walley T. 2004. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead, UK: Open University Press.
37. Mossialos EM, Srivastava D. 2008. Pharmaceutical policies in Finland: challenges and opportunities; Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; Ministry of Social Affairs and Health Finland.
38. MSF. 2005. The beginning of the end of affordable generics. Press Release, Médicins Sans Frontières.
39. MSH & WHO. 2004. International Drug Price Indicator Guide, 2004 edition. Cambridge, MA: Management Sciences for Health.
40. Nakamba P, Hanson K, McPake B. 2002. Markets for hospital services in Zambia. International Journal of Health Planning and Management 17: 229-247
41. Oxfam. 2002. TRIPS and public health: the next battle. Oxfam briefing paper. Oxford: Oxfam.
42. Patton MQ. 2002. Qualitative research and evaluation. 3rd edition. Thousand Oaks, CA: Sage Publications.
43. Ramsey FP. 1927. A contribution to the theory of taxation. Economic Journal 37: 47-61.
44. Schmalensee R, Willig RD. 1989. Handbook of industrial organisation. Vol.1. Amsterdam: North-Holland.
45. Sertel MR. 1988. Regulation by participation. Journal of Economics 48: 111-134
46. Smith WR. 1956. Product differentiation and market segmentation as alternative marketing strategies. Journal of Marketing 21: 3-8.
47. Stigler GJ. 1963. The theory of price. 3rd edition. London: Macmillan.
48. Stigler GJ, Sherwin RA. 1985. The extent of the market. Journal of Law and Economics 28: 555-585
49. Sweeny K. 2004. Australian pharmaceutical pricing in a global context: trends and issues. Pharmaceutical Industry Project Working Paper No. 16. Melbourne: Centre for Strategic Economic Studies, Victoria University.
50. Tirole J. 1988. The theory of industrial organization. Vol.1. Cambridge, MA: MIT Press.
51. UNDP. 2004. Human development report 2004. Cultural liberty in today's diverse world. New York: The United Nations Development Programme.
52. UNDP. 2006. Mozambique. National human development report. Maputo: UNDP Mozambique.
53. Wagstaff A, van Doorslaer E. 2003. Catastrophe and impoverishment in paying for health care: with applications to Vietnam 1993-1998. Health Economics 12: 921-934
54. WHO. 2003. Effective medicines regulation: ensuring safety, efficacy and quality. Geneva: World Health Organization. WHO/EDM/2003.2.
55. WHO. 2004a. Equitable access to essential medicines: a framework for collective action. WHO Policy Perspectives on Medicines, no.8. Geneva: World Health Organization. WHO/EDM/2004.4.
56. WHO. 2004b. The World Medicine Situation. Geneva: World Health Organization. WHO/EDM/PAR/2004.5.
57. WHO Commission on Macroeconomics, and Health. 2001. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization.
58. WHO and HAI. 2003. Medicine prices: a new approach to measurement. Geneva: World Health Organization and Health Action International.
59. World Bank. 2005. Mozambique - Country Economic Memorandum.
60. Sustaining Growth and Reducing Poverty. Report No. 32615-MZ. World Bank Africa Region.
61. Zwanzinger J, Melnick G, Rye KM. 1994. Hospital and antitrust: Defining markets, setting standards. Journal of Health Politics, Policy and Law 19: 423-447